The protocol by Qi Wen-wei, titled “Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial”, raises an important clinical question. The upstream therapeutic intervention will be performed with valsartan alone, valsartan and fluvastatin, calcium channel blocker (CCB) alone, CCB and fluvastatin in close to two thousand randomly drawn patients from 15 centers across China.

The possible flaw is lack of blinding, this however is not disqualifying the manuscript from the publication.

I maintain the authors’ attention on writing the study groups (abstract/manuscript). Authors describe the groups as follow: “This study was designed to examine whether valsartan and/or fluvastatin can reduce the probability of non-permanent AF in patients with hypertension.”.

Meanwhile, in line with the Flow-process diagram the studied arms concern the groups:
1/ valsartan alone;
2/ valsartan AND fluvastatin
3/ CCB AND fluvastatin
4/ CCB alone.

The authors did not test the effect of fluvastatin alone, so in my opinion the formulation “valsartan and/or fluvastatin” is not correct.

I have no further major comments.